黑人美国CKD患者中可溶性尿激酶型纤溶酶原激活物受体的研究
基于AASK试验及其队列阶段(中位随访9.7年),在黑人美国CKD患者中,基线血清suPAR每升高1个标准差(对数转换后),CKD进展风险增加26%,ESKD风险增加36%,全因死亡风险增加25%,且独立于GFR和蛋白尿;suPAR仅在与两个APOL1风险等位基因患者的蛋白尿恶化相关。
要点
- 血清suPAR升高与黑人CKD患者CKD进展、ESKD和死亡风险独立相关。
- suPAR与蛋白尿恶化的关联仅见于携带两个APOL1风险等位基因的患者。
- suPAR的关联独立于碘125酞酸酯测量的GFR和蛋白尿。
核心结论
- 在黑人美国CKD患者中,较高的suPAR与多种不良结局相关,且独立于蛋白尿和GFR,无论是否携带APOL1肾病风险变异。
研究设计与样本
- 利用非洲裔美国人肾脏病与高血压研究(AASK)的多中心临床试验及队列阶段数据,中位总随访9.7年(四分位距6.5-10.9年)。
主要发现
- 基线suPAR中位数为4462 pg/ml,平均测量GFR为46 ml/min/1.73 m2,24小时尿蛋白肌酐比中位数为80 mg/g。
- 控制基线人口学、随机化分组、GFR、蛋白尿、APOL1风险状态及临床危险因素后,基线对数转换suPAR每升高1个标准差,CKD进展风险增加1.26倍(HR 1.26;95%CI 1.11-1.43;P<0.001)。
- 较高的suPAR亦独立与ESKD风险(HR 1.36;95%CI 1.17-1.58;P<0.001)和死亡风险(HR 1.25;95%CI 1.08-1.45;P=0.003)相关。
- suPAR仅在与携带两个APOL1风险等位基因的患者中与蛋白尿恶化相关(HR 1.46;95%CI 1.08-1.99;P=0.02)。
临床怎么用
- 在黑人CKD患者中,检测血清suPAR可能有助于识别CKD进展、ESKD和死亡高风险个体,但需结合APOL1风险状态解读蛋白尿恶化风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Black Americans with and without APOL1 kidney disease risk variants face high risk of ESKD. Soluble urokinase-type plasminogen activator receptor (suPAR), a circulating signaling protein and marker of immune activation, constitutes a promising biomarker of CKD-associated risks. We aimed to quantify the associations between serum suPAR concentration and adverse outcomes in Black Americans with and without APOL1 kidney disease risk variants, over and above iodine-125 iothalamate measured GFR and proteinuria. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Using data from the African-American Study of Kidney Disease and Hypertension, a multicenter clinical trial followed by a cohort phase with a median total follow-up of 9.7 years (interquartile range, 6.5-10.9 years), we examined the associations of suPAR with CKD progression (defined as doubling of serum creatinine or ESKD), ESKD, worsening proteinuria (defined as pre-ESKD doubling of 24-hour urine protein-to-creatinine ratio to ≥220 mg/g), and all-cause death. RESULTS: At baseline, the median suPAR was 4462 pg/ml, mean measured GFR was 46 ml/min per 1.73 m2, and median 24-hour urine protein-to-creatinine ratio was 80 mg/g. After controlling for baseline demographics, randomization arm, GFR, proteinuria, APOL1 risk status, and clinical risk factors, there was a 1.26-times higher risk for CKD progression per SD higher baseline log-transformed suPAR (hazard ratio [HR], 1.26; 95% confidence interval [95% CI], 1.11 to 1.43; P<0.001). Higher suPAR was also independently associated with risk of ESKD (HR, 1.36; 95% CI, 1.17 to 1.58; P<0.001) and death (HR, 1.25; 95% CI, 1.08 to 1.45; P=0.003). suPAR was only associated with worsening proteinuria in patients with two APOLI risk alleles (HR, 1.46; 95% CI, 1.08 to 1.99; P=0.02). CONCLUSIONS: Higher suPAR was associated with various adverse outcomes in Black Americans with CKD, with and without APOL1 kidney disease risk variants, independently of proteinuria and GFR.
引用
- Luo S, Coresh J, Tin A, et al. Soluble Urokinase-Type Plasminogen Activator Receptor in Black Americans with CKD. Clin J Am Soc Nephrol. 2018. PMID: 29903900. doi:10.2215/CJN.13631217
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。